Drug Sales Trends for ASACOL HD

Annual Sales Revenues and Units Sold for ASACOL HD

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ASACOL HD			2021
ASACOL HD			2020
ASACOL HD			2019
ASACOL HD			2018
ASACOL HD			2017

Market Analysis and Sales Projections for Asacol HD

Introduction

Asacol HD, a formulation of mesalamine, is a crucial drug in the treatment of ulcerative colitis (UC), a type of inflammatory bowel disease (IBD). This article provides a comprehensive market analysis and sales projections for Asacol HD, highlighting its significance, market dynamics, and future outlook.

Disease Overview: Ulcerative Colitis

Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the inner lining of the colon and rectum. The symptoms include abdominal pain, diarrhea, and rectal bleeding. The disease requires ongoing management to induce and maintain remission[1].

Market Significance of Asacol HD

Asacol HD, containing mesalamine (5-aminosalicylic acid or 5-ASA), is renowned for its safety profile and efficacy in treating UC. It is considered the gold standard for mesalamine products due to its anti-inflammatory and immunosuppressive actions[1].

Competitive Landscape

The UC market is competitive, with several biologic and biosimilar drugs entering the scene. Key events include the launch of Johnson & Johnson's Simponi and Takeda's Entyvio, as well as the anticipated launch of biosimilars following the patent expiry of blockbusters like Remicade and Humira. Despite this, Asacol HD maintains its position due to its well-established safety and efficacy profile[1].

Sales Forecast and Market Analysis

Historical Performance

Asacol HD has been a significant player in the UC market. Prior to its discontinuation, Asacol (the predecessor to Asacol HD) had substantial sales. Even after its discontinuation in 2013, residual sales volumes continued to impact the market[5].

Current Market

The global mesalamine market, which includes Asacol HD, was valued at approximately USD 5.7 billion in 2023 and is projected to reach around USD 8.4 billion by 2033, growing at a CAGR of 3.9% from 2024 to 2033[4].

Regional Performance

• North America: This region holds the largest market share for mesalamine, including Asacol HD, due to a well-established healthcare infrastructure and high prevalence of IBD[4].
• Europe: Europe is the second-largest market, driven by a well-developed healthcare system and high awareness about IBD and available treatments[4].
• Asia-Pacific: This region is expected to witness the highest growth rate, driven by increasing incidence of IBD, rising healthcare expenditure, and growing awareness about the disease and treatments in countries like China, India, and Japan[4].

Distribution Channels

Asacol HD is primarily distributed through:

• Outpatient Retail Pharmacies: Approximately 70% of packages are distributed through this channel[5].
• Mail-Order/Specialty Pharmacies: About 23% of packages are distributed through this channel[5].
• Non-Retail Settings: Around 7% of packages are distributed through non-retail settings[5].

Market Drivers

Increasing Prevalence of IBD

The growing incidence of ulcerative colitis and Crohn's disease worldwide is a significant driver for the mesalamine market, including Asacol HD[3][4].

Government Healthcare Policies

Enhanced healthcare policies for IBD patients, particularly in regions like Asia-Pacific, are boosting the market growth[3].

Technological Advancements

The development of novel drug delivery systems, such as extended-release and multi-matrix formulations, improves patient compliance and treatment outcomes, driving market growth[4].

Market Challenges

Unmet Clinical Needs

High levels of unmet clinical needs in ulcerative colitis and the side effects of medications are key challenges that hamper the growth of the 5-aminosalicylates drugs market, including Asacol HD[3].

Competitive Pressure

The entry of biosimilars and new biologic drugs increases competitive pressure, potentially affecting the sales of branded drugs like Asacol HD[1].

Future Outlook

The future outlook for Asacol HD remains promising despite the competitive landscape. Here are some key points:

Continued Dominance of Oral Formulations

Oral mesalamine formulations, particularly extended-release and targeted delivery systems, are expected to maintain their dominance in the market[4].

Growing Use in Crohn's Disease

The use of mesalamine in managing mild to moderate Crohn's disease is expected to grow, contributing to the overall market expansion[4].

Regional Growth

Asia-Pacific is anticipated to witness the highest growth rate due to increasing incidence of IBD, rising healthcare expenditure, and growing awareness about the disease and treatments[4].

Key Takeaways

• Asacol HD is a significant player in the UC market due to its safety and efficacy profile.
• The global mesalamine market is projected to grow at a CAGR of 3.9% from 2024 to 2033.
• North America and Europe are the largest markets, with Asia-Pacific expected to show the highest growth rate.
• Distribution is primarily through outpatient retail pharmacies.
• Market growth is driven by increasing IBD prevalence, government healthcare policies, and technological advancements.

FAQs

What is Asacol HD used for?

Asacol HD is used for the treatment of ulcerative colitis, a type of inflammatory bowel disease.

What is the active ingredient in Asacol HD?

The active ingredient in Asacol HD is mesalamine (5-aminosalicylic acid or 5-ASA).

What is the projected market size for mesalamine by 2033?

The global mesalamine market is projected to reach around USD 8.4 billion by 2033[4].

Which region is expected to witness the highest growth rate in the mesalamine market?

The Asia-Pacific region is expected to witness the highest growth rate in the mesalamine market[4].

What are the main distribution channels for Asacol HD?

The main distribution channels for Asacol HD are outpatient retail pharmacies, mail-order/specialty pharmacies, and non-retail settings[5].

Sources

1. Research and Markets: "Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022"[1].
2. CNBC TV18: "Zydus Life Dips Over 5% After Teva Gets US FDA Approval For Asacol HD Generic"[2].
3. Growth Plus Reports: "5-Aminosalicylates Drugs Market Forecast 2031"[3].
4. Data Horizon Research: "Mesalamine Market Size, Share & Forecast 2033"[4].
5. FDA: "Delzicol Safety and Drug Utilization Review"[5].